Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (not Kiora Pharmaceuticals as indicated in metadata) on March 23, 2020. The filing discloses the execution of a new employment agreement with the Company's Chief Financial Officer, Sarah Romano, following approval by the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
- Base Salary: $275,000 annually.
- Performance Bonus: Target of up to 30% of annual base salary.
- Severance (Termination without Cause/Good Reason): 6 months of base salary, 50% of the maximum target bonus, and 6 months of COBRA premiums.
- Equity Acceleration: 6 months of vesting acceleration upon termination without Cause/Good Reason; full acceleration upon Change of Control.
Material Changes
The material change reported is the formalization of the CFO's compensation package via a new Employment Agreement dated March 23, 2020. No financial performance changes or operational shifts are reported in this document.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary contingency disclosed relates to the financial obligations triggered by the termination of the CFO's employment or a Change of Control of the Company.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the current status of Ms. Romano's unvested stock options and restricted stock awards to assess potential dilution or expense acceleration.
- Note the discrepancy between the metadata company name (Kiora Pharmaceuticals) and the filing registrant (EyeGate Pharmaceuticals).